This study used ISAR and has shown considerable overlap of inflammatory biomarkers in severe asthma, suggesting that a more comprehensive approach – rather than relying on simple biomarker threshold positivity – is needed to identify the best therapy for patients. The ISAR is the largest international registry of severe asthma patients, with high-quality, patient-level, real-world, standardized data collected from countries across the world.
#research #asthma #dataanalytics #health
ISAR is conducted by the Observational & Pragmatic Research Institute, and co-funded by Optimum Patient Care Global Ltd and AstraZeneca
Click on the link below to see the full article: